<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:department>School of Medicine</gtr:department><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B4C10884-D8C6-4E2F-971C-85A035C6A0A0"><gtr:id>B4C10884-D8C6-4E2F-971C-85A035C6A0A0</gtr:id><gtr:firstName>Robert James</gtr:firstName><gtr:surname>Salmond</gtr:surname><gtr:orcidId>0000-0002-1807-1056</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FP026206%2F1"><gtr:id>06C51E31-03E4-440F-96FA-E5D46428866A</gtr:id><gtr:title>IMPC: Role of asparagine synthetase in anti-tumour T cell responses</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/P026206/1</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Background:
T cells are white blood cells that have a key role in the immune responses that protect the body from the development and spread of cancer. Immune responses to tumours rely on the ability of T cells to specifically recognise components (antigens) of cancer cells that are not present on normal non-cancerous tissue. Upon encounter with a cancer antigen, a T cell undergoes a process of activation and division to generate a population of effector cells that then traffic through the body to the tumour site. This requires a lot of energy and nutrients to fuel the processes of cell growth, division and activation. In addition, within the tumour site, to maintain an effective immune response, T cells have to compete with tumour cells for nutrients. Indeed, nutrient deprivation within the tumour environment is thought to contribute to the failure of T cell immune responses in cancer.
Aims:
We are interested in determining how T cells cope with the energy demands required for effective anti-tumour responses. We wish to test the hypothesis that T cells increase their capacity to synthesize a key amino acid, asparagine, which serves as a building block for the generation of new proteins. We will determine the role of an enzyme called asparagine synthetase (AS) in this process by comparing the ability of control mice and mice lacking AS to generate T cell responses to tumour cells. Furthermore, we will compare the ability of control and AS-deficient T cells to undergo activation, growth and cell division in tissue culture to determine the role of asparagine
synthesis in these fundamental processes.
Output:
These preliminary analyses will determine whether AS is important for T cell immune responses. By understanding the Fundamental mechanisms by which T cell responses are fuelled, in the future, we hope to use this knowledge to develop approaches to improve immune responses to cancer.</gtr:technicalSummary><gtr:fund><gtr:end>2018-01-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2017-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>35205</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">MR/P026206/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>